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The reliability and applicability of the preparation of the three, for nuclear medi-
cine very important, 99mTc-radiopharmaceuticals from the inactive (technetium-cold)
kit solutions were tested. Each examined commercial kit was dissolved in saline (0.9 %
NaCl). The conditions of the storage of the inactive kit solutions till labeling were exam-
ined. The main problem is the stablity of the reductant stannous ions which is very diffi-
cult to predict. To stabilize and ensure a good quality of the labeled radiopharma-
ceuticals, ascorbic or gentisic acid were added. It was found that the best results were ob-
tained by keeping the samples frozen at –20 ºC. Both stabilizers can be used but for an ef-
fective protection much lower concentrations of ascorbic acid are needed. Its concentra-
tions of 12–60 g/ml of the kit, stabilized dimercaptosuccinate (DMS) and pyro-
phosphate (PyP) for about 7–8 days. The solution of 2,3-dicarboxypro-
pane-1,1-diphosphonate (DPD) was found to be stable even without the stabilizer. This
could be attributed probably to the chemical nature of this complex. However, in routine
praxis the applied procedure demands great care and personel very experienced in
radiopharmacy.
Keywords: Radiopharmaceuticals, technetium-99m, dimercaptosuccinate, dicarboxy-
propane diphosphonate, pyrophosphate.
INTRODUCTION
To make a short-lived radioisotope available at any site in the word, regardless of
the distance from the production center, is a rather complicated task. In the case of
6-hour 99mTc two main innovations enabled the construction of an adequate frame-
work. The first was the development of 99Mo/99mTc generators. In short, the concept of
a radionuclide generator is based on the effective separation of a decaying, longer-lived
parent and the daughter radionuclide of shorter half-life so that the daughter is obtained
in a pure radionuclidic and radiochemical form. The most common is the chromato-
graphic generator based on fission-produced 99Mo. Separation of 99mTc from the lon-
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ger lived 99Mo by elution with saline, is performed by the end-user, often very far from
the production center. Several reviews cover different types and aspects of 99Mo/99mTc
generators.1 The introduction of the evacuated vial technique of elution made a very
important contribution to generator technology. It eliminated the exposure of the
column to water and its consequent radiolysis and limited the possiblity of microbial
contamination. Thus, a fresh daily supply of sterile, pyrogen-free eluate 99mTc is en-
sured.
The second milestone was the development of 99mTc-radiopharmaceuticals by
the method which is now known also as “instant kit” preparation. It appeared in the lit-
erature for the first time in 1971.2 Althought the basic chemistry was poorly understood
at that time, the first generation of radiopharmaceuticals, targeting specific organs and
tissues in an organism, was soon developed. Generally, technetium previously reduced
by stannous ions to lower valence states, reacts with donor ligands. The ligands coordi-
nate the metal forming complexes which target specific organs and tissues in the human
body. The modern instant kit comprises stannous ions, ligands, additives, buffers, etc, in
lyophilised form in a glass vial under vacuum or in a nitrogen atmosphere. The
shelf-life of such a kit, determined experimentally, is usually up to several months under
certain storage conditions. Labeling is performed by addition of 99mTc, obtained by elu-
tion of the generator. This procedure is also called the reconstitution of the kit.
Decristiforo et al.3 investigated the applicability of the procedure for the cost ef-
fective use of several kits. Instead in 99mTc eluate, the lyophylized content of the kit vial
was dissolved (reconstituted) in pure saline. The technetium-cold (inactive) solution
was then kept at low temperature and labeled on demand.
This approach was preliminary tested on freshly prepared solutions of pyro-
phosphate.4 In this work the investigations were extended to three important commer-
cial kits in order to determine the reliability of the proposed method for its possible rou-
tine clinical application. Two osteotropic preparations, pyrophosphate (PyP) and
2,3-dicarboxypropane-1,1-diphosphonate (DPD), as well as dimercaptosuccinate
(DMS) which is, after labeling with 99mTc, used for the visualization of kidneys, were
examined. Ascorbic and gentisic acid were tested as stabilizers. In the experiments, dif-
ferent amounts of the stabilizers were added to the kit solutions and the content of 99mTc
pertechnetate was determined in dependance on time and temperature of storage of the
reconstituted kit.
EXPERIMENTAL
The DMS and PyP kits were prepared from commercially purchased chemicals. DPD was lab-
oratory - synthesized.5 Technetium-99m was obtained by elution of a 99Mo/99mTc generator. The kits
and the generator are commercially produced in the Laboratory for Radioisotopes (Vin~a Institute of
Nuclear Sciences). Stannous chloride dihydrate (Merck), ascorbic (Merck) and gentisic acid (Fluka)
were commercial p.a. grade chemicals.
The “cold” kits were reconstituted by addition of a given volume of the home-made saline so-
lution, divided into 2 ml-fractions and kept either at –20 ºC or at 5 ºC. After definite time intervals, the
fractions were thawed and labeled by addition of 0.2–0.3 ml of 99mTc eluate (30–74 MBq 99mTc).
The experiments were performed on the following samples:
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a) 2-ml fractions of the kits, without any stabilizer, kept either at –20 ºC or at 5 ºC
b) 2-ml fractions of the kits containing either 12 or 60 g of ascorbic acid per ml, kept either at
–20 ºC or at 5 ºC
c) 2-ml fractions of the kits containing either 100, 200 or 500 g of gentisic acid per ml, kept
either at –20 ºC or at 5 ºC.
The content of 99mTc pertechnetate was determined by ascending paper chromatography on
Whatman No. 1 paper with acetone as the mobile phase. 99mTc-pertechnetate migrates with the sol-
vent front (Rf = 1) while the labeled preparation and reduced, hydrolyzed 99mTc remain at the start (Rf
= 0). The paper was cut into 1-cm pieces and counted in a well-type gamma counter (Gamma 333,
ICN, Belgium).
RESULTS AND DISCUSSION
The lyophilized content of the kit vial was reconstituted (dissolved) in 99mTc
eluate. The obtained solution was then divided into a certain number of individual doses
for the patients. It happens commonly in routine praxis that at least a part of the 99mTc
kit remains unused and has to be rejected. The proposed procedure3 should avoid these
losses and ensure a cost effective use of the kits. The basic difference, in comparison to
the usual procedure, is that the content of the vial is dissolved in pure saline instead in
99mTc eluate. Afraction of technetium-cold solution (without 99mTc) which will not be
used is separated and labeled later on demand.
It is important to ensure that 99mTc radiopharmaceuticals of adequate quality are
obtained. Therefore, appropriate storage conditions should be determined, as well as
the time span during which such a kit solution can be reliably used.
This approach was first tested on freshly prepared solutions of pyrophosphate.4
In the experiments, presented in this paper, the proposed method was applied to the so-
lutions obtained by the reconstitution of the three commercially available kits: DMS,
DPD and PyP.
On the basis of previous results, it was concluded that storage of the samples at
low temperature as the only protection can not ensure a stable quality of the labeled
preparation. The content of 99mTc-pertechnetate rises, thus lowering the required
radiochemical purity of the kit. The presence of some chemicals as stabilizers was
found to be necessary. So, in the present experiments, the kit samples contained either
ascorbic or gentisic acid as chemical stabilizers.
In principle, labeling efficiency of radiopharmaceuticals depends on several fac-
tors, such as the concentration of the ligand and stannous ions, molar ratio ligand/re-
ductant, pH and time of reaction. The composition of the solutions of the kits used in the
experiments and in the major fields of application of 99mTc(Sn)-DMS, 99mTc(Sn)-DPD
and 99mTc(Sn)-PyP are presented in Table I.
Asanexampleof thestabilizationpattern,Table II showstheresultsobtainedwith the
dispensed solutions of PyP. The content of 99mTc-pertechnetate in dependence on the con-
centration of ascorbic acid, as well as on the temperature and time of storage are given.
It is arbitrarily taken that a kit is considered as stabilized if the content of
99mTc-pertechnetate does not exceed 5 %.
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TABLE I. Composition of the solutions of DMS, DPD and PyP and the fields of application of
99mTc-labeled radiopharmaceuticals
Kit
Volume of
the “cold”
kit/ml
Ligand/
mol/ml
Reductant/mol
SnCl2/ml
L/R pH Applications of
99mTc
radiopharmaceuticals Ref.
DMS 8 1.37 0.445 3.1 3–4
Renal scintigraphy; measure-
ment of renal fixation; deter-
mination of kidney function
6
DPD 10 3.74 0.223 16.8 7–8 Skeletal scintigraphy 5
PyP 6 22.4 0.89 25.2 5–6 Bone and joint scintigraphy 7
According to the data presented in Table II, it can be seen that already the lowest
examined concentration of ascorbic acid (12 g/ml) is sufficient to keep the content of
99mTc-pertechnetate far below 5 % for five days in the samples stored at a low tempera-
ture (–20 ºC).
TABLE II. Content of free 99mTc-pertechnetate in the dispensed 99mTc(Sn)-PyP in dependence on the
concentration of ascorbic acid, temperature and time of storage
Storage temperature –20 ºC 5 ºC
Time of storage days
Content of
asc. acid/g/ml
Content of
99mTcO4-/%
Content of
asc. acid/g/ml
Content of
99mTcO4- /%
0 2.80.3 0 3.50.2
1 12 0.20.1 12 0.60.2
60 0.20.1 60 0.60.3
0 4.53 0 –
5 12 0.20.1 12 –
60 0.30.1 60 –
7 0 – 0 9.31.3
12 0.30.1 12 0.20.1
The investigations show that both ascorbic and gentisic acid can be used as chem-
ical stabilizers. Generally, there is no substantial difference in the mode of stabilization.
Therefore, the results obtained by using gentisic acid are not shown separately.
The effect of ascorbic acid on the stabilization of DMS, PDP and PyP in depend-
ence on its concentration, as well as on the time and temperature of storage is shown in
Table III, in which the concentrations and time during which the radiopharmaceutical is
stabilized, i.e., the content of 99mTc is 5 % or less, are given.
The content of free 99mTc-pertechnetate in the DMS and PyPdepends on the con-
centration of the stabilizer. However, the desired degree of protection is achieved with
much lower concentrations of ascorbic (12–60 g/ml) than gentisic acid. To achieve a
similar effect much higher concentrations of gentisic acid have to be used. Up to
100–200 g/ml of gentisic acid stabilizes DMS for only about 2 days storage at –20 ºC
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but for longer storage times even much higher concentrations of gentisic acid (500
g/ml) were found to have no effect. This high concentration of the stabilizer results in
colorization of the kit solution. The possible negative effect on the biodistribution of the
labeled kit would also have to be tested. This finding also has practical meaning–ascor-
bic acid is a better chemical stabilizer and is also less expensive than gentisic acid.
The results presented in Table III indicate that the stability of kit solution samples
depends both on the content of ascorbic acid and on the storage conditions. The lower
storage temperature (–20 ºC) is favourable. Together with the use of ascorbic acid it en-
ables the production of labeled radiopharmaceuticals DMS and PyP, which are stable
up to about 7–8 days after dispensing of the inactive solution.
TABLE III. Time of stabilization (days) of DMS, DPD and PyP in dependence on the concentration of
ascorbic acid and temperature of storage
Storage temperature – 20 ºC 5 ºC
Kit
Content of asc.
acid/g/ml
Time of stabili-
zation/days
Content of
99mTcO4–/ %
Time of stabili-
zation/days
Content of
99mTcO4– /%
DMS 0 1 4.500.5 1  1
12 1
 1 2 1.80.4
60 7
 1 2  1
DPD 0 7
 1 5  1
12 7
 1 5  1
PyP 0 1 2.80.3 1 3.50.2
12 8
 1 7  1
However, by analysing the data given in Table III it can be concluded that the sta-
bility of the kit solutions depends also on some other factors. Generally, the main prob-
lem which occurs is the stability of stannous ions which is difficult to predict. The na-
ture of the prepared complex should also be taken into account. The DPD kit has the
highest stability among the examined kits and although it contains the smallest concen-
tration of the reductant Sn(II), it is stable even without ascorbic acid.
CONCLUSIONS
The reliability of the use of fractionated technetium-cold kits in the preparation of
the three 99mTc radiopharmaceuticals was tested. Three important kits for application in
nuclear medicine, DMS, DPD and PyP, were examined. The obtained results show that
the cold kit should be stored at low temperatures (–20 ºC). Ascorbic and gentisic acids
were applied as chemical stabilizers. Ascorbic acid was found to be more suitable as
much lower concentrations were needed to achieve the desired stability. In the cases of
DMS and PyP, about 12–60 g/ml of ascorbic acid stabilize the kits for 7—8 days after
dispensing. DPD was found to be highly stable even without a stabilizer. The results
show that this method could be a promising possibility for a cost effective use of
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99mTc-radiopharmaceuticals. However, they also illustrate the difficulties which could
arise in routine clinical practice. It is very difficult to predict the stability of stannous
ions, as it depends also on the nature of the ligand, the presence of other components,
differences in the production batches, etc. Therefore it seems that the proposed method
can only be applied with great care and by people experienced in radiopharmacy.
I Z V O D
STABILIZACIJA Tc-99m RADIOFARMACEUTIKA HEMIJSKIM ADITIVIMA
JURIJ VU^INA i NADE@DA VUKI]EVI]
Laboratorija za radioizotope, Institut za nuklearne nauke "Vin~a", p. pr. 522, 11001 Beograd
Ispitan je postupak efikasnog i ekonomi~nog iskori{}ewa tri komercijalna,
za nuklearnu medicinu vrlo va`na 99mTc radiofarmaceutika. On se, za razliku od
standardnog (rastvarawe u eluatu 99mTc), zasniva na rastvarawu liofilizovanog sa-
dr`aja bo~ice sa preparatom u neaktivnom, ~istom fiziolo{kom rastvoru 0,9% NaCl.
U radu odre|eni su uslovi i vreme ~uvawa ovakvih rastvora koji obezbe|uju da se, po
obele`avawu 99mTc, dobiju radiofarmaceutici odgovaraju}e radiohemijske ~isto}e.
Rastvori preparata, sa ili bez antioksidansa askorbinske ili 2,5-dihidroksi-ben-
zoeve kiseline, do obele`avawa ~uvaju se na sni`enoj temperaturi. Oba hemijska sta-
bilizatora mogu se primeniti, ali su za postizawe dobrih rezultata potrebne znatno
ni`e koncentracije askorbinske kiseline. Wene koncentracije od 12–60 g/ml do-
voqne su za stabilizaciju dimerkapto-sukcinata (DMS) i pirofosfata (PyP) tokom
7–8 dana od razlivawa. Na|eno je da je 2,3-dihidroksi-1,1-propandifosfonat (DPD)
stabilan i bez dodatka stabilizatora. To se mo`e objasniti prirodom kompleksa. Me-
|utim, nedostatak ovog postupka za rutinsku primenu je u tome {to wegova pouzdanost
ne zavisi samo od koncentracije reaktanata i uslova ~uvawa ve} i od prirode liganda i
drugih faktora.
(Primqeno 3. marta, revidirano 4. jula 2001)
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